NDUFC2
ENSG00000151366
Target class
Enzyme
Chromosome
11
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFC2
- Gene name
- NADH:ubiquinone oxidoreductase subunit C2
- Gene symbol
- NDUFC2
- Protein name
- NADH dehydrogenase [ubiquinone] 1 subunit C2 (Complex I-B14.5b) (CI-B14.5b) (Human lung cancer oncogene 1 protein) (HLC-1) (NADH-ubiquinone oxidoreductase subunit B14.5b)
- B14.5b
- HLC-1
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 98.43
- Tissue specificity (Gini)
- 0.16
- Tissue specificity (tau)
- 0.495
- KEGG gene identifiers
- hsa:4718
- Protein interaction confidence
- 0.940616
- Protein interaction partners
- 86
- R-HSA-611105
- R-HSA-6798695
- R-HSA-6799198
- End position
- 78081871
- Start position
- 78068297
- Chromosome
- 11
- Strand
- Reverse
- Mitochondrion inner membrane
- Single-pass membrane protein
- Matrix side .
- Mitochondria
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.494649
- Expression inequality (Gini)
- 0.160356
Expression in transcripts per million
- Adrenal Gland
- 98.43
- Brain - Cerebellar Hemisphere
- 97.61
- Thyroid
- 94.95
- Brain - Cerebellum
- 82.24
- Brain - Frontal Cortex (BA9)
- 75.24
Expression in transcripts per million
- Adrenal Gland98.43
- Brain - Cerebellar Hemisphere97.61
- Thyroid94.95
- Brain - Cerebellum82.24
- Brain - Frontal Cortex (BA9)75.24
- Cells - Cultured fibroblasts65.12
- Pituitary63.42
- Fallopian Tube60.04
- Brain - Hypothalamus58.51
- Cervix - Endocervix58
- Muscle - Skeletal57.81
- Uterus57.8
- Brain - Cortex56.96
- Artery - Coronary56.5
- Artery - Aorta56.38
- Brain - Spinal cord (cervical c-1)55.25
- Breast - Mammary Tissue54.92
- Brain - Anterior cingulate cortex (BA24)53.61
- Adipose - Visceral (Omentum)53.43
- Brain - Nucleus accumbens (basal ganglia)52.67
- Artery - Tibial52.62
- Nerve - Tibial51.97
- Adipose - Subcutaneous51.88
- Ovary50.83
- Testis50.66
And 29 more, listed on the interactive page.
Biological processes
- GO:0032981
- GO:0005737
- GO:0005739
- GO:0005743
- GO:0005886
- GO:0035577
- GO:0045271
Molecular functions
- GO:0005515
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor